Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Head and neck cancers

5466 - Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)


20 Oct 2018


Poster Discussion session - Head and neck cancers


Staging and Imaging;  Translational Research

Tumour Site

Head and Neck Cancers


Stefano Cavalieri


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


S. Cavalieri1, L. De Cecco2, G. Calareso3, M. Silva4, S.E. Gazzani4, M. Bologna5, I. Nauta6, F. Wesseling7, L. Lopez Perez8, R. Shefi9, V. Tountopoulos10, G. Fico8, K. Scheckenbach11, R.H. Brakenhoff6, F. Hoebers12, S. Canevari2, T. Poli13, L. Licitra14, L. Mainardi5, B. BD2Decide Consortium15

Author affiliations

  • 1 Head And Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Platform Of Integrated Biology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 3 Radiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 4 Radiology Unit, University of Parma and Azienda Ospedaliero Universitaria di Parma, Parma/IT
  • 5 Department Of Electronics, Information And Bioengineering, Politecnico di Milano, Milan/IT
  • 6 Department Of Otolaryngology And Head & Neck Surgery, VU University Medical Center Amsterdam, Amsterdam/NL
  • 7 Grow - School Of Oncology And Developmental Biology, Maastricht University Medical Centre, Maastricht/NL
  • 8 Universidad Politécnica De Madrid, LifeSTech, Madrid/ES
  • 9 All In Image Ltd, All in Image, Israel/IL
  • 10 Athens Technology Center Sa, Innovation Lab, Athens/GR
  • 11 Department Of Otorhinolaryngology, Universitätklinikum Düsseldorf, Düsseldorf/DE
  • 12 Department Of Radiation oncology, Maastricht University Medical Centre, Maastricht/NL
  • 13 Maxillofacial Surgery Unit, University of Parma and Azienda Ospedaliero Universitaria di Parma, Parma/IT
  • 14 Head And Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan/IT
  • 15 Bd2decide Consortium, BD2Decide, Parma/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5466


The 5-years overall survival (OS) for OSCC is 60%. TNM staging is group-based and it is limited in tailoring personalized therapy. GF on primary tumor is a mature method to identify prognostic markers, but is limited by availability of surgical specimen. RF, based on techniques being already part of the diagnostic phase, is feasible in all pts, but techniques are not yet defined. We recently defined a prognostic 48-genes signature (48-GS) in OSCC. Association and integration of GR and RF could pave the way to non-invasive assessment of prognostic models. We considered the series of OSCC pts with clinical stage III/IV from 5 European centers enrolled in the ongoing BD2Decide project.


Primary tumors were analyzed for gene expression by ClariomD (Affymetrix). Several clinical and GF were tested and their prognostic value was compared to TNM. Magnetic resonance imaging (MRI) radiomics was evaluated on diffusion weighted images acquired at different b-values (0, 50, 100, 500, 1000) and on ADC maps. A total of 641 features were computed on tumor volume, including First Order Statistics (FOS), Textural and Shape-and-size RFs. A cohort of 87 pts with available data for both GF and MRI RF was analyzed. According to 48-GS, pts were divided in 2 classes: high and low risk. Statistical difference of RF was evaluated in the 2 classes using Mann-Whitney test with FDR correction.


The 48-GS separated the OSCC OS significantly better than TNM (p < 0.001). When challenged against available demographic and clinical factors, this model retained a significant independent association in multivariate Cox regression analysis. Five RF of the FOS group computed on fast ADC map were statistically different between the two 48-GS classes (p < 0.05). External validation of association between RF and GF is ongoing.


We identified a prognostic model based on the 48-GS able to improve assessment of stage III/IV OSCC risk based on OS. Since significantly altered RFs mainly describe the variability of the intensity signals inside the tumor, their association with 48-GS could mirror biological differences.

Clinical trial identification


Legal entity responsible for the study

BD2Decide Consortium.


AIRC (AIRC IG 18519); EU Horizon 2020 research/innovation program (689715).

Editorial Acknowledgement


L. Licitra: Honoraria or advisory role: Eisai, MSD, Boehringer Ingelheim, Novartis, AstraZeneca, Roche, BMS, Merck-Serono, Bayer, Debiopharm, Sobi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.